851904-80-8 Usage
Uses
Used in Metal Processing Industry:
1-(biphenyl-4-yl)-3-propylthiourea is used as a corrosion inhibitor for protecting metals from corrosion during processing.
Used in Pharmaceutical Industry:
1-(biphenyl-4-yl)-3-propylthiourea is used as a potential pharmaceutical agent due to its potential biological activity and ability to serve as a ligand for various receptors or enzymes.
Further research is needed to fully understand the potential uses and effects of 1-(biphenyl-4-yl)-3-propylthiourea.
Check Digit Verification of cas no
The CAS Registry Mumber 851904-80-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,1,9,0 and 4 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 851904-80:
(8*8)+(7*5)+(6*1)+(5*9)+(4*0)+(3*4)+(2*8)+(1*0)=178
178 % 10 = 8
So 851904-80-8 is a valid CAS Registry Number.
InChI:InChI=1/C16H18N2S/c1-2-12-17-16(19)18-15-10-8-14(9-11-15)13-6-4-3-5-7-13/h3-11H,2,12H2,1H3,(H2,17,18,19)
851904-80-8Relevant articles and documents
Synthesis and biological evaluation of arylthiourea derivatives with antitubercular activity
Luo, Rusong,Laitinen, Tuomo,Teng, Liyan,Nevalainen, Tapio,Lahtela-Kakkonen, Maija,Zheng, Baofu,Wang, Honghai,Poso, Antti,Zhang, Xuelian
, p. 640 - 650 (2013/08/23)
Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.
